Hisham Shiblaq - Jan 3, 2023 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Signature
/s/ Alaleh Nouri, Attorney-in-Fact for Hisham Shiblaq
Stock symbol
PRCT
Transactions as of
Jan 3, 2023
Transactions value $
-$888,210
Form type
4
Date filed
1/5/2023, 03:09 PM
Previous filing
Apr 4, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Sale -$387K -9.74K -19.79% $39.76 39.5K Jan 3, 2023 Direct F1, F2, F3
transaction PRCT Common Stock Sale -$219K -5.42K -13.74% $40.47 34K Jan 3, 2023 Direct F1, F4
transaction PRCT Common Stock Sale -$263K -6.31K -18.52% $41.74 27.7K Jan 3, 2023 Direct F1, F5
transaction PRCT Common Stock Sale -$18.5K -466 -1.68% $39.74 27.3K Jan 4, 2023 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 9, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 Includes 931 shares acquired on May 13, 2022 and 500 shares acquired on November 14, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $41.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.35 to $42.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.44 to $40.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.